Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lanzhou Univ. CDK6 compound 2f
- Development stage
- Unknown
- Lead developer
- Lanzhou University
01
Overview
Lanzhou Univ. CDK6 compound 2f: sourced facts only. name: "Further structural modifications led to the synthesis of additional derivatives and PROTAC molecules, ultimately identifying a more potent CDK6 inhibitor, compound 2f, with an IC50 of 0.56 ± 0.06 μM in AGS cells." [PMID:40561885]; target: "Further structural modifications led to the synthesis of additional derivatives and PROTAC molecules, ultimately identifying a more potent CDK6 inhibitor, compound 2f, with an IC50 of 0.56 ± 0.06 μM in AGS cells." [PMID:40561885]; developer: "School of Pharmacy, Lanzhou University, No. 199 Donggang West Road, Lanzhou 730000, PR China; School of Pharmacy, Tsinghua University, Beijing 100084, PR China." [PMID:40561885]
02
Targets
CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on Lanzhou Univ. CDK6 compound 2f.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lanzhou Univ. CDK6 compound 2f.